BFRG BULLFROG AI HOLDINGS

BullFrog AI Files 2022 Annual Report on Form 10-K

BullFrog AI Files 2022 Annual Report on Form 10-K

GAITHERSBURG, Md., April 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced it filed its Form 10-K with the Securities and Exchange Commission (“SEC”) for its year ended December 31, 2022.

"While our 10-K largely mirrored the S-1 we filed for our IPO, the first-time nature of this filing required additional work and resources that delayed its official submission to the SEC, which prompted a compliance notice from Nasdaq. We are pleased to report that the completion of the 10-K filing has rectified this situation, and we do not anticipate similar delays with future filings," said BullFrog AI’s founder and CEO Vin Singh.

BullFrog AI received notice from Nasdaq on April 20, 2023, notifying the Company that it was not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because the Company's Annual Report on Form 10-K for the year ended December 31, 2022 was not filed with the Securities and Exchange Commission by the required due date. The Company is now in compliance with Nasdaq Listing Rule 5250(c)(1).

About BullFrog AI

BullFrog AI is a digital technology company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may seek to receive the therapies they need.

For more information visit BullFrogAI at

Website:

LinkedIn:

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Dave Gentry

RedChip Companies, Inc.



800-733-2447

SOURCE: BullFrog AI Holdings, Inc.



EN
25/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BULLFROG AI HOLDINGS

 PRESS RELEASE

BullFrog AI Expands Sales and Marketing Team to Accelerate Commercial ...

BullFrog AI Expands Sales and Marketing Team to Accelerate Commercial Adoption of Clinical Trial Optimization Solutions and bfPREP™ Module GAITHERSBURG, Md., Sept. 30, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the expansion of its internal sales organization to support accelerated commercialization of the Company’s clinical trial optimization offerings, includin...

 PRESS RELEASE

BullFrog AI and Sygnature Discovery Announce Official Sales Launch of ...

BullFrog AI and Sygnature Discovery Announce Official Sales Launch of BullFrog Data Networks™ to Global Biopharma Clients Sales launch marks pivotal commercial milestone, unlocking up to $30 million in potential revenue through 2028 GAITHERSBURG, Md., Sept. 25, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its collaboration with Sygnature Discovery, a leading...

 PRESS RELEASE

BullFrog AI to Showcase AI-Powered Clinical Data Solutions in Xtalks W...

BullFrog AI to Showcase AI-Powered Clinical Data Solutions in Xtalks Webinar GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, that its Director of AI, Machine Learning & Innovation, Juan Felipe Beltrán Lacouture, PhD, will present a hosted by Xtalks titled “Clinical Data Analysis with Agents: Reliable Automation with Human Oversight.” The webinar will tak...

 PRESS RELEASE

BullFrog AI’s bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact ...

BullFrog AI’s bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration Joint oncology conference submission planned and follow-on contract discussion underway Validates BullFrog AI’s enterprise-grade platform strategy, combining automation and human-in-the-loop oversight for scalable, trustworthy analytics GAITHERSBURG, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful ...

 PRESS RELEASE

BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference

BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, CEO, will participate in a fireside chat and one-on-one meetings at BTIG’s Annual Virtual Biotechnology Conference, being held Tuesday, July 29 through Wednesday, July 30. Fireside Presentation De...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch